View Older Stories View More Recent Stories

Jun 8, 2018 08:53AM Zealand Pharma (ZEAL) Phase 3 Trial of Dasiglucagon Met Primary and Secondary Objectives
Jun 8, 2018 08:50AM Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
May 31, 2018 08:20AM Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.
May 31, 2018 05:11AM Zealand Pharma will attend the Jefferies Global Healthcare Conference on June 5-8, 2018 in New York
May 31, 2018 05:10AM Zealand announces amendments to its Articles of Association following the granting of warrants
May 29, 2018 05:50AM Zealand Pharma (ZEAL) Announces Complete Second Pivotal Phase 3 trial with Dasiglucagon for Treatment of Severe Hypoglycemia
May 28, 2018 05:20AM Zealand Pharma reports completion of the second and pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia
May 16, 2018 09:00AM Zealand Pharma - Interim report for the first quarter of 2018
May 14, 2018 06:57AM Zealand hosts conference call on May 16 at 4 pm CET/10 am EDT to present first quarter results 2018
May 2, 2018 06:28AM Zealand Pharma to attend Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018
Apr 27, 2018 01:34AM Zealand announces net sales of Soliqua® 100/33 and Lyxumia®/Adlyxin® for the first quarter of 2018
Apr 26, 2018 05:47AM Zealand Pharma (ZEAL) Reports Successful End-of-Phase 2 Meeting with FDA on Glepaglutide for Short Bowel Syndrome
Apr 26, 2018 12:51AM Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome
Apr 19, 2018 11:16AM Zealand's Annual General Meeting in 2018
Apr 12, 2018 02:15AM Zealand Pharma will attend the Kempen Life Science Conference on April 18, 2018 in Amsterdam
Apr 11, 2018 07:55AM Zealand and Roche Diabetes Care enter Phase 3 study collaboration for treatment of congenital hyperinsulinism with dasiglucagon
Mar 22, 2018 04:17AM Zealand Pharma to present at the Needham Healthcare Conference, March 27, 2018 in New York
Mar 20, 2018 08:56AM Zealand Pharma's first Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia successfully meets its primary objective
Feb 7, 2018 01:34AM Zealand reports royalty revenue for the fourth quarter of 2017
Jan 25, 2018 11:01AM Zealand Pharma hosts Capital Market Day: Accelerating the late stage pipeline
Jan 23, 2018 08:17AM Zealand Pharma to present Phase 2 results on glepaglutide at the ASPEN 2018 Conference in Las Vegas, U.S.
Jan 23, 2018 02:17AM New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome (SBS)
Jan 19, 2018 05:31PM Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half 2018
Jan 19, 2018 03:09AM Zealand Pharma strengthens its Management by appointing Ivan Møller as SVP, Technical Development & Operations
Jan 3, 2018 07:46AM Zealand Pharma major shareholder announcement: Wellington Management Group LLP, U.S.
Dec 21, 2017 09:47AM Zealand Pharma boosts collaboration with Beta Bionics to advance development of its dasiglucagon in the iLetTM
Dec 21, 2017 04:12AM Zealand Pharma: Invitation to Capital Market Day in New York on 25 January, and event in Copenhagen on 29 January 2018
Dec 7, 2017 09:36AM Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
Dec 1, 2017 03:20AM Employee elected board member change in Zealand Pharma
Nov 30, 2017 03:08AM Financial calendar for Zealand Pharma in 2018
Nov 29, 2017 04:38AM Zealand Pharma to attend three U.S. healthcare conferences in December
Nov 20, 2017 08:53AM Zealand increases its share capital as a consequence of exercise of employee warrants
Nov 14, 2017 02:37AM Recruitment completed in trial to evaluate the optimal dosing frequency for Zealand's long-acting GLP-2 analog glepaglutide
Nov 7, 2017 08:48AM Zealand Pharma will attend the Jefferies Healthcare Conference in London and the Bryan Garnier & Co Healthcare Conference in Paris, both in November
Nov 2, 2017 02:40AM Zealand reports royalty revenue for the third quarter of 2017
Oct 24, 2017 06:45AM Zealand Pharma (ZEAL) Confirms FDA Granted Orphan Drug Designation to Glepaglutide for Treatment of Short Bowel Syndrome
Oct 24, 2017 06:44AM U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome
Oct 12, 2017 07:05AM Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide
Sep 22, 2017 03:12AM Zealand increases its share capital as a consequence of exercise of employee warrants
Aug 9, 2017 10:08AM Zealand Pharma (Nasdaq: ZEAL) to Ring The Nasdaq Stock Market Opening Bell
Jul 31, 2017 01:36AM Zealand reports royalty revenue for the second quarter of 2017
Jul 3, 2017 02:30AM Zealand initiates first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
Jun 12, 2017 02:49AM Zealand to regain control of elsiglutide
Jun 10, 2017 01:16PM New analysis shows Soliqua® 100/33 lowered HbA1c by more than 2% in patients with screening levels greater than 9%
Jun 10, 2017 01:09PM Dasiglucagon (pINN) presentation at the 77th Scientific Sessions of the American Diabetes Association (ADA) indicate use for treatment of severe hypoglycemia
Jun 2, 2017 03:27AM Zealand to present at two international healthcare investor conferences in June 2017
May 17, 2017 09:25AM CORRECTION: Zealand reports results for the first three months of 2017 (unaudited)
May 17, 2017 09:06AM Zealand reports results for the first three months of 2017 (unaudited)
May 11, 2017 02:59AM Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim
Apr 28, 2017 02:11AM Zealand reports Q1 2017 royalty revenue
View More Recent Stories View Older Stories